- Recommendation ID
- NG131/8
- Question
What is the effectiveness and cost effectiveness of different scheduling of zoledronic acid in the prevention and reduction of skeletal events in people with hormone-refractory prostate cancer?
- Any explanatory notes
(if applicable)
Source guidance details
- Comes from guidance
- Prostate cancer: diagnosis and management
- Number
- NG131
- Date issued
- May 2019
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 09/05/2019 |